Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 12/20 | 0.42 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | TGM2 | P21980 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20503302 | 1.00 | CASP1 (0.42) | CASP1FOLH1CA12CA1CA2 | |
| SCHEMBL17285797 | 0.92 | CASP1 (0.41) | CASP1CA12CA1CA2CA4 | |
| SCHEMBL20503217 | 0.80 | PPARA (0.50) | FOLH1 | |
| SCHEMBL20503216 | 0.80 | PPARA (0.50) | FOLH1 | |
| SCHEMBL20504173 | 0.78 | TGM2 (0.51) | TGM2ALDH1A1 | |
| SCHEMBL2464156 | 0.78 | MEN1 (0.49) | — | |
| SCHEMBL22283053 | 0.77 | ALDH1A1 (0.50) | CASP1ALDH1A1 | |
| SCHEMBL22283051 | 0.77 | ALDH1A1 (0.50) | CASP1ALDH1A1 | |
| SCHEMBL19017843 | 0.77 | SIRT2 (0.46) | TGM2ALDH1A1 | |
| SCHEMBL17661281 | 0.76 | SIRT2 (0.50) | TGM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3378495-B1 | COMPOSITION COMPRISING NOVEL GLUTAMIC ACID DERIVATIVE AND BLOCK COPOLYMER, AND USE THEREOF | NIPPON KAYAKU KK (JP) | 2020-08-05 | — | — | EP | disclosed |
| US-20200190101-A1 | Composition Containing Novel Glutamic Acid Derivative And Block Copolymer, And Use Thereof | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2020-06-18 | — | — | US | disclosed |
| EP-3378495-A1 | COMPOSITION COMPRISING NOVEL GLUTAMIC ACID DERIVATIVE AND BLOCK COPOLYMER, AND USE THEREOF | Nippon Kayaku Kabushiki Kaisha (JP) | 2018-09-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200190101-A1 | Composition Containing Novel Glutamic Acid Derivative And Block Copolymer, And Use Thereof | GGCT, GGT1, TGM2 | CASP1 4468/4885FOLH1 26/4885CA12 389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.